For example, KRAS and BRAF mutations have been routinely used to exclude anti-EGFR therapy in CRC patients 44, while MSI (microsatellite instable) predicts responsiveness of CRCs to anti-PD-1 immunotherapy 45. This evidence concerns the gene KRAS and colorectal carcinoma.